<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01967576</url>
  </required_header>
  <id_info>
    <org_study_id>140001</org_study_id>
    <secondary_id>14-C-0001</secondary_id>
    <nct_id>NCT01967576</nct_id>
  </id_info>
  <brief_title>Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma</brief_title>
  <official_title>Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
        -  Most treatments for malignant pheochromocytomas/paragangliomas (PHEO/PGL) are palliative&#xD;
           and multidisciplinary. Chemotherapy using the combination of cyclophosphamide,&#xD;
           vincristine, and dacarbazine has been successfully utilized in the management of rapidly&#xD;
           progressive metastatic PHEO, with more than 50% complete or partial tumor response and&#xD;
           more than 70% complete or partial biochemical response.&#xD;
&#xD;
        -  Vascular endothelial growth factor (VEGF) expression and evidence of angiogenesis has&#xD;
           been found in many PHEO/PGL, so it is plausible that interfering with VEGF signaling may&#xD;
           result in anti-tumor activity in patients with PHEO/PGL.&#xD;
&#xD;
        -  Axitinib (AG-013736) is an oral, potent and selective inhibitor of vascular endothelial&#xD;
           growth factor (VEGF) receptors 1, 2, and 3. Pre-clinical data suggests that the&#xD;
           anti-tumor activity of axitinib may result from its anti-angiogenic activity and that&#xD;
           this is reversible when treatment is discontinued.&#xD;
&#xD;
        -  Given the known clinical safety and efficacy of axitinib, an assessment of its activity&#xD;
           in PHEO/PGL and its impact on the VEGF pathway in PHEO/PGL could provide valuable&#xD;
           information.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  Determine the response rate of metastatic PHEO/PGL to axitinib (AG-013736).&#xD;
&#xD;
        -  Determine the progression-free survival of metastatic PHEO/PGL treated with axitinib&#xD;
           (AG-013736).&#xD;
&#xD;
        -  Explore the relationship of potential biological markers of axitinib activity with&#xD;
           clinical outcomes.&#xD;
&#xD;
        -  Perform pharmacogenomics analyses of drug metabolism and transport proteins through&#xD;
           germline deoxyribonucleic acid (DNA) examination.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Adults with a confirmed pathologic diagnosis of PHEO/PGL by the Laboratory of Pathology,&#xD;
           National Cancer Institute (NCI)&#xD;
&#xD;
        -  Biochemical evidence of PHEO/PGL&#xD;
&#xD;
        -  Imaging confirmation of metastatic, locally advanced or unresectable disease.&#xD;
&#xD;
        -  Measurable disease at presentation&#xD;
&#xD;
        -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2&#xD;
&#xD;
        -  Patients must not have received prior therapy with a tyrosine kinase (TK) inhibitor&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Phase II, open label, non-randomized trial&#xD;
&#xD;
        -  Patients with metastatic pheochromocytoma/paraganglioma will receive axitinib (AG-013736&#xD;
           twice a day (BID)) in eight-week cycles&#xD;
&#xD;
        -  Patients will be evaluated for response every eight weeks using Response Evaluation&#xD;
           Criteria in Solid Tumors (RECIST) criteria&#xD;
&#xD;
        -  Tumor biopsies are not mandatory but every attempt will be made to obtain these from&#xD;
           patients prior to starting axitinib and again 20 - 30 days after treatment has begun.&#xD;
&#xD;
        -  Approximately 12 to 37 patients will be needed to achieve the objectives of the trial&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
        -  Most treatments for malignant pheochromocytomas/paragangliomas (PHEO/PGL) are palliative&#xD;
           and multidisciplinary. Chemotherapy using the combination of cyclophosphamide,&#xD;
           vincristine, and dacarbazine has been successfully utilized in the management of rapidly&#xD;
           progressive metastatic PHEO, with more than 50% complete or partial tumor response and&#xD;
           more than 70% complete or partial biochemical response.&#xD;
&#xD;
        -  Vascular endothelial growth factor (VEGF) expression and evidence of angiogenesis has&#xD;
           been found in many PHEO/PGL, so it is plausible that interfering with VEGF signaling may&#xD;
           result in anti-tumor activity in patients with PHEO/PGL.&#xD;
&#xD;
        -  Axitinib (AG-013736) is an oral, potent and selective inhibitor of vascular endothelial&#xD;
           growth factor (VEGF) receptors 1, 2, and 3. Pre-clinical data suggests that the&#xD;
           anti-tumor activity of axitinib may result from its anti-angiogenic activity and that&#xD;
           this is reversible when treatment is discontinued.&#xD;
&#xD;
        -  Given the known clinical safety and efficacy of axitinib, an assessment of its activity&#xD;
           in PHEO/PGL and its impact on the VEGF pathway in PHEO/PGL could provide valuable&#xD;
           information.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
        -  Determine the response rate of metastatic PHEO/PGL to axitinib (AG-013736).&#xD;
&#xD;
        -  Determine the progression-free survival of metastatic PHEO/PGL treated with axitinib&#xD;
           (AG-013736).&#xD;
&#xD;
        -  Explore the relationship of potential biological markers of axitinib activity with&#xD;
           clinical outcomes.&#xD;
&#xD;
        -  Perform pharmacogenomics analyses of drug metabolism and transport proteins through&#xD;
           germline deoxyribonucleic acid (DNA) examination.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Adults with a confirmed pathologic diagnosis of PHEO/PGL by the Laboratory of Pathology,&#xD;
           National Cancer Institute (NCI)&#xD;
&#xD;
        -  Biochemical evidence of PHEO/PGL&#xD;
&#xD;
        -  Imaging confirmation of metastatic, locally advanced or unresectable disease.&#xD;
&#xD;
        -  Measurable disease at presentation&#xD;
&#xD;
        -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2&#xD;
&#xD;
        -  Patients must not have received prior therapy with a tyrosine kinase (TK) inhibitor&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Phase II, open label, non-randomized trial&#xD;
&#xD;
        -  Patients with metastatic pheochromocytoma/paraganglioma will receive axitinib (AG-013736&#xD;
           twice a day (BID)) in eight-week cycles&#xD;
&#xD;
        -  Patients will be evaluated for response every twelve weeks (+/- 1 week) using Response&#xD;
           Evaluation Criteria in Solid Tumors (RECIST) criteria&#xD;
&#xD;
        -  Approximately 12 to 37 patients will be needed to achieve the objectives of the trial&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 19, 2013</start_date>
  <completion_date type="Actual">December 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 29, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinical Response (Partial Response + Complete Response)</measure>
    <time_frame>Patients were assessed every 12 weeks (+/- week) up to 40.6 months</time_frame>
    <description>Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or no-target) must have reduction in short axis to &lt;10 mm. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression - Free Survival (PFS)</measure>
    <time_frame>time from start of treatment to time of progression or death, up to 5 years and 9 months</time_frame>
    <description>PFS is defined as the duration of time from start of treatment to time of progression or death, whichever comes first. Disease progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vascular Endothelial Growth Factor Receptors (VEGFR) in Blood in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The measurement of VEGFR in blood will be performed using a semi-quantitative immunohistochemistry assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacogenomics Analyses</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Measuring genetic alterations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma Levels of Axitinib</measure>
    <time_frame>Baseline and 3 years</time_frame>
    <description>Pharmacokinetic analysis will be done to determine drug levels in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)</measure>
    <time_frame>Date treatment consent signed to date off study, approximately 54 months and 29 days.</time_frame>
    <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Pheochromocytoma</condition>
  <condition>Paraganglioma</condition>
  <arm_group>
    <arm_group_label>1/Arm 1-Axitinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Axitinib 5 mg twice a day on a 28-day cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Axitinib (AG-013736)</intervention_name>
    <description>5 mg twice a day on a 28-day cycle.</description>
    <arm_group_label>1/Arm 1-Axitinib</arm_group_label>
    <other_name>INLYTA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA&#xD;
&#xD;
        2.1.1 Adults with a confirmed pathologic diagnosis of pheochromocytoma/paraganglioma by the&#xD;
        Laboratory of Pathology, National Cancer Institute (NCI) when such tissue is available to&#xD;
        confirm or&#xD;
&#xD;
        In the event that outside tissue is not available:&#xD;
&#xD;
          -  an outside pathology report confirms the diagnosis of Pheo-PGI, AND&#xD;
&#xD;
          -  the patient has nuclear medicine imaging studies that would only be positive in an&#xD;
             adult patient with a diagnosis of Pheo/PGL (Fluorodopa (F-DOPA), Dotatate, F-Dopamine&#xD;
             or Metaiodobenzylguanidine (MIBG))&#xD;
&#xD;
        2.1.1.1 Imaging confirmation of metastatic disease&#xD;
&#xD;
        2.1.1.2 Measurable disease at the time of enrollment per Response Evaluation Criteria in&#xD;
        Solid Tumors (RECIST) 1.1.&#xD;
&#xD;
        2.1.1.3 A life expectancy of at least 3 months and Eastern Cooperative Oncology Group&#xD;
        (ECOG) performance status less than or equal to 2&#xD;
&#xD;
        2.1.1.4 Age greater than or equal to 18 years. Because no dosing or adverse event data are&#xD;
        currently available on the use of Axitinib in patients &lt;18 years of age, children are&#xD;
        excluded from this study, but will be eligible for future pediatric trials.&#xD;
&#xD;
        2.1.1.5 Information available or pending regarding possible genetic alterations that can&#xD;
        explain the patient's pheochromocytoma/paraganglioma (mutations in succinate&#xD;
        dehydrogenase-B (SDHB), SDHV or Von Hippel-Lindau (VHL) genes)&#xD;
&#xD;
        2.1.1.6 Last dose of chemotherapy or experimental therapy more than 4 weeks (6 weeks in the&#xD;
        case of nitrosourea) prior to enrollment date; 2 weeks if the last therapy was received as&#xD;
        part of a phase 0 or exploratory Investigational New Drug (IND) trial. Last surgery more&#xD;
        than 4 weeks prior to enrollment, to allow for wound healing. Core biopsies or fine needle&#xD;
        aspiration (FNA) will not require any waiting period&#xD;
&#xD;
        2.1.1.7 Last radiotherapy treatment greater than or equal to 4 weeks prior to starting&#xD;
        treatment with this protocol and there must be sites of measurable disease that did not&#xD;
        receive radiation&#xD;
&#xD;
        2.1.1.8 Prior therapeutic Metaiodobenzylguanidine (MIBG) is allowed&#xD;
&#xD;
        2.1.1.9 Organ and marrow function as defined below:&#xD;
&#xD;
        2.1.1.10 Total bilirubin less than or equal to 1.5 x upper limit of normal (ULN) (upper&#xD;
        limit of normal), unless the patient meets the criteria for Gilbert's Syndrome. The upper&#xD;
        limit value for bilirubin for subjects with Gilbert's Syndrome is less than 3 mg/dl.&#xD;
&#xD;
        Note: A diagnosis of Gilbert's disease will be made in the presence of (1) unconjugated&#xD;
        hyperbilirubinemia noted on several occasions; (2) normal results from complete blood count&#xD;
        (CBC) count, reticulocyte count, and blood smear; (3) normal liver function test results;&#xD;
        and (4) an absence of other disease processes that can explain the unconjugated&#xD;
        hyperbilirubinemia.&#xD;
&#xD;
        2.1.1.11 Aspartate aminotransferase (AST) less than or equal to 2.5 x ULN, alanine&#xD;
        aminotransferase (ALT) less than or equal to 2.5 x ULN&#xD;
&#xD;
        2.1.1.12 Amylase and lipase equal to, or less than, the institutional ULN.&#xD;
&#xD;
        2.1.1.13 Creatinine clearance greater than or equal to 40 ml/min (estimated or measured&#xD;
        creatinine clearance) or serum creatinine less than or equal to 1.6 mg/dl&#xD;
&#xD;
        2.1.1.14 Random urine protein &lt; 20 mg/dL. If greater than or equal to 20 mg/dL then a&#xD;
        24-hour urine protein collection will be performed to accurately demonstrate that the&#xD;
        24-hour total is &lt;1000 mg, the level acceptable for enrollment on study&#xD;
&#xD;
        2.1.1.15 Absolute neutrophil count greater than or equal to 500/mm(3)&#xD;
&#xD;
        2.1.1.16 Platelet count greater than or equal to 50,000/ mm(3)&#xD;
&#xD;
        2.1.1.17 Ability to understand and sign an informed consent document.&#xD;
&#xD;
        2.1.1.18 Ability and willingness to follow the guidelines of the clinical protocol&#xD;
        including visits to National Institute of Child Health and Human Development (NICHD) and&#xD;
        National Cancer Institute (NCI), Bethesda, Maryland for treatment and follow up visits.&#xD;
&#xD;
        2.1.1.19 Because the effects of chemotherapy on the developing human fetus are potentially&#xD;
        harmful, women of childbearing potential and men who participate in the study must agree to&#xD;
        use adequate contraception (hormonal or barrier methods) before, during the study and for a&#xD;
        period of 3 months after the last dose of chemotherapy.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
        2.1.2.1 Patients with pheochromocytoma/paraganglioma tumors potentially curable by surgical&#xD;
        excision alone as determined by the Principal Investigator in discussions with the surgical&#xD;
        consultants&#xD;
&#xD;
        2.1.2.2 Patients who have large abdominal masses impinging on bowel or pulmonary masses&#xD;
        with encroached vessels and a potential to bleed will be considered on case by case basis&#xD;
        after careful consultation with multiple disciplines such as radiologists and surgeons with&#xD;
        main intent being patient safety.&#xD;
&#xD;
        2.1.2.3 Unstable hypertension defined as a systolic blood pressure &gt;150 mm Hg or diastolic&#xD;
        pressure &gt; 90 mmHg despite optimal medical management.&#xD;
&#xD;
        2.1.2.4 Untreated brain metastases (or local treatment of brain metastases within the last&#xD;
        6 months) due to the poor prognosis of these patients and difficulty ascertaining the cause&#xD;
        of neurologic adverse events.&#xD;
&#xD;
        2.1.2.5 Pregnancy, due to the possible adverse effects on the developing fetus.&#xD;
&#xD;
        2.1.2.6 Lactating women who are breast-feeding due to the possibility of transmitting&#xD;
        axitinib to the child.&#xD;
&#xD;
        2.1.2.7 The presence of a second malignancy, other than squamous cell carcinoma of the skin&#xD;
        or in situ cervical cancer because it will complicate the primary objective of the study.&#xD;
        Cancer survivors who have been free of disease for at least two years can be enrolled in&#xD;
        this study.&#xD;
&#xD;
        2.1.2.8 Patients with evidence of a bleeding diathesis&#xD;
&#xD;
        2.1.2.9 Patients must not have received prior therapy with a tyrosine kinase inhibitor&#xD;
        (TKI). Prior TKI usage in pheochromocytoma affects the same pathway as axitinib.&#xD;
&#xD;
        2.1.2.10 Gastrointestinal abnormalities including:&#xD;
&#xD;
          -  Inability to take oral medications&#xD;
&#xD;
          -  Requirement for intravenous alimentation&#xD;
&#xD;
          -  Prior surgical procedure affecting absorption including total gastric resection&#xD;
&#xD;
          -  Treatment for active peptic ulcer disease in the past 6 months&#xD;
&#xD;
          -  Active gastrointestinal bleeding, unrelated to cancer, as evidenced by hematemesis,&#xD;
             hematochezia or melena in the past 3 months without evidence of resolution documented&#xD;
             by endoscopy or colonoscopy&#xD;
&#xD;
          -  Malabsorption syndrome&#xD;
&#xD;
        2.1.2.11 Current use or anticipated need for treatment with drugs that are known potent&#xD;
        Cytochrome P450 3A4 (CYP3A4) inhibitors (i.e., grapefruit juice, verapamil, ketoconazole,&#xD;
        miconazole, itraconazole, erythromycin, telithromycin, clarithromycin, indinavir,&#xD;
        saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, amprenavir, fosamprenavir, and&#xD;
        delavirdine).&#xD;
&#xD;
        2.1.2.12 Current use or anticipated need for treatment with drugs that are known CYP3A4 or&#xD;
        Cytochrome P450 1A2, (CYP1A2) inducers (i.e., carbamazepine, dexamethasone, felbamate,&#xD;
        omeprazole, phenobarbital, phenytoin, amobarbital, nevirapine, primidone, rifabutin,&#xD;
        rifampin, and St. John's wort).&#xD;
&#xD;
        2.1.2.13 Requirement of anticoagulant therapy with oral vitamin K antagonists. Low-dose&#xD;
        anticoagulants for maintenance of patency of central venous access devices or prevention of&#xD;
        deep venous thrombosis is allowed. Therapeutic use of low molecular weight heparin is&#xD;
        allowed.&#xD;
&#xD;
        2.1.2.14 Active seizure disorder or evidence of brain metastases, spinal cord compression,&#xD;
        or carcinomatous meningitis.&#xD;
&#xD;
        2.1.2.15 Any of the following within 12 months prior to study drug administration:&#xD;
        myocardial infarction, uncontrolled angina, coronary/peripheral artery bypass graft,&#xD;
        symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack&#xD;
        and within 6 months before study drug administration for deep vein thrombosis or pulmonary&#xD;
        embolism.&#xD;
&#xD;
        2.1.2.16 Other severe acute or chronic medical or psychiatric condition, or laboratory&#xD;
        abnormality that may increase the risk associated with study participation or study drug&#xD;
        administration, or may interfere with the interpretation of study results, and in the&#xD;
        judgment of the investigator would make the patient inappropriate for entry into this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea B Apolo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2014-C-0001.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Stein PP, Black HR. A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution's experience. Medicine (Baltimore). 1991 Jan;70(1):46-66. Review.</citation>
    <PMID>1988766</PMID>
  </reference>
  <reference>
    <citation>Pacak K, Linehan WM, Eisenhofer G, Walther MM, Goldstein DS. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med. 2001 Feb 20;134(4):315-29. Review.</citation>
    <PMID>11182843</PMID>
  </reference>
  <reference>
    <citation>Bravo EL. Pheochromocytoma: new concepts and future trends. Kidney Int. 1991 Sep;40(3):544-56.</citation>
    <PMID>1787652</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>October 19, 2013</study_first_submitted>
  <study_first_submitted_qc>October 19, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2013</study_first_posted>
  <results_first_submitted>October 22, 2019</results_first_submitted>
  <results_first_submitted_qc>August 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 31, 2020</results_first_posted>
  <last_update_submitted>December 16, 2020</last_update_submitted>
  <last_update_submitted_qc>December 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute (NCI)</investigator_affiliation>
    <investigator_full_name>Andrea Apolo, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Mutation in SDHB gene</keyword>
  <keyword>Mutation in SDHV gene</keyword>
  <keyword>Mutation in VHL gene</keyword>
  <keyword>Pharmacogenomics analyses</keyword>
  <keyword>Germline DNA examination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pheochromocytoma</mesh_term>
    <mesh_term>Paraganglioma</mesh_term>
    <mesh_term>Carotid Body Tumor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Axitinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT01967576/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 18, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT01967576/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1/Arm 1-Axitinib</title>
          <description>Axitinib 5 mg twice a day on a 28-day cycle&#xD;
Axitinib (AG-013736): 5 mg twice a day on a 28-day cycle.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressed/Removed from treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study closing at site</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused further treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>1/Arm 1-Axitinib</title>
          <description>Axitinib 5 mg twice a day on a 28-day cycle&#xD;
Axitinib (AG-013736): 5 mg twice a day on a 28-day cycle.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.66" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Response (Partial Response + Complete Response)</title>
        <description>Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or no-target) must have reduction in short axis to &lt;10 mm. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).</description>
        <time_frame>Patients were assessed every 12 weeks (+/- week) up to 40.6 months</time_frame>
        <population>2/14 participants were not evaluated for this outcome measure. Current Investigator inherited this trial when the original investigator left the National Institutes of Health (NIH). The reason participants were not evaluated is unknown.</population>
        <group_list>
          <group group_id="O1">
            <title>1/Arm 1-Axitinib</title>
            <description>Axitinib 5 mg twice a day on a 28-day cycle&#xD;
Axitinib (AG-013736): 5 mg twice a day on a 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Response (Partial Response + Complete Response)</title>
          <description>Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Partial Response (PR) is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete Response (CR) is disappearance of all target lesions. Any pathological lymph nodes (whether target or no-target) must have reduction in short axis to &lt;10 mm. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive Disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).</description>
          <population>2/14 participants were not evaluated for this outcome measure. Current Investigator inherited this trial when the original investigator left the National Institutes of Health (NIH). The reason participants were not evaluated is unknown.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Confirmed Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression - Free Survival (PFS)</title>
        <description>PFS is defined as the duration of time from start of treatment to time of progression or death, whichever comes first. Disease progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).</description>
        <time_frame>time from start of treatment to time of progression or death, up to 5 years and 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1/Arm 1-Axitinib</title>
            <description>Axitinib 5 mg twice a day on a 28-day cycle&#xD;
Axitinib (AG-013736): 5 mg twice a day on a 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression - Free Survival (PFS)</title>
          <description>PFS is defined as the duration of time from start of treatment to time of progression or death, whichever comes first. Disease progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" lower_limit="3.3" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Vascular Endothelial Growth Factor Receptors (VEGFR) in Blood in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma</title>
        <description>The measurement of VEGFR in blood will be performed using a semi-quantitative immunohistochemistry assay.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Blood samples were collected on a subset of participants, but assays were never performed on any of the samples and therefore no data for the Outcome Measures were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>1/Arm 1-Axitinib</title>
            <description>Axitinib 5 mg twice a day on a 28-day cycle&#xD;
Axitinib (AG-013736): 5 mg twice a day on a 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Vascular Endothelial Growth Factor Receptors (VEGFR) in Blood in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma</title>
          <description>The measurement of VEGFR in blood will be performed using a semi-quantitative immunohistochemistry assay.</description>
          <population>Blood samples were collected on a subset of participants, but assays were never performed on any of the samples and therefore no data for the Outcome Measures were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacogenomics Analyses</title>
        <description>Measuring genetic alterations.</description>
        <time_frame>up to 3 years</time_frame>
        <population>Blood samples were collected on a subset of participants, but assays were never performed on any of the samples and therefore no data for the Outcome Measures were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>1/Arm 1-Axitinib</title>
            <description>Axitinib 5 mg twice a day on a 28-day cycle&#xD;
Axitinib (AG-013736): 5 mg twice a day on a 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacogenomics Analyses</title>
          <description>Measuring genetic alterations.</description>
          <population>Blood samples were collected on a subset of participants, but assays were never performed on any of the samples and therefore no data for the Outcome Measures were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma Levels of Axitinib</title>
        <description>Pharmacokinetic analysis will be done to determine drug levels in blood.</description>
        <time_frame>Baseline and 3 years</time_frame>
        <population>Blood samples were collected on a subset of participants, but assays were never performed on any of the samples and therefore no data for the Outcome Measures were collected.</population>
        <group_list>
          <group group_id="O1">
            <title>1/Arm 1-Axitinib</title>
            <description>Axitinib 5 mg twice a day on a 28-day cycle&#xD;
Axitinib (AG-013736): 5 mg twice a day on a 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Levels of Axitinib</title>
          <description>Pharmacokinetic analysis will be done to determine drug levels in blood.</description>
          <population>Blood samples were collected on a subset of participants, but assays were never performed on any of the samples and therefore no data for the Outcome Measures were collected.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)</title>
        <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
        <time_frame>Date treatment consent signed to date off study, approximately 54 months and 29 days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1/Arm 1-Axitinib</title>
            <description>Axitinib 5 mg twice a day on a 28-day cycle&#xD;
Axitinib (AG-013736): 5 mg twice a day on a 28-day cycle.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)</title>
          <description>Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Date treatment consent signed to date off study, approximately 54 months and 29 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>1/Arm 1-Axitinib</title>
          <description>Axitinib 5 mg twice a day on a 28-day cycle&#xD;
Axitinib (AG-013736): 5 mg twice a day on a 28-day cycle.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Duodenal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="10" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Mitral valve disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pulmonary valve disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Tricuspid valve disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>External ear inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hearing impaired</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="6" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="28" subjects_affected="9" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="44" subjects_affected="7" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="25" subjects_affected="9" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rectal mucositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="14" subjects_affected="6" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="33" subjects_affected="13" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchial infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Conjunctivitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Duodenal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rhinitis infective</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cardiac troponin I increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="15" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="42" subjects_affected="12" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="16" subjects_affected="6" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Serum amylase increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="6" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="7" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="4" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Buttock pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Muscle weakness lower limb</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Muscle weakness upper limb</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="7" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Personality change</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, cystocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, hydronephrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspareunia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Perineal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vaginal inflammation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vaginal stricture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Vaginismus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Laryngopharyngeal dysesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pulmonary edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Voice alteration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Nail loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia syndrome</sub_title>
                <counts group_id="E1" events="12" subjects_affected="6" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Skin induration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="345" subjects_affected="14" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Andrea Apolo</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>301-480-0536</phone>
      <email>apoloab@nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

